Medical Oncology/Institute of Cancer Sciences, The Christie NHS Foundation Trust/University of Manchester, Manchester, United Kingdom.
Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Hepatology. 2021 Jun;73(6):2311-2325. doi: 10.1002/hep.31598.
Intrahepatic cholangiocarcinoma (iCCA) with liver metastases is perceived to have a poor prognosis, but the American Joint Committee on Cancer (AJCC) classifies them as early stage in the absence of lymph nodes or extrahepatic spread.
Patients with iCCA from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) and Surveillance, Epidemiology, and End Results (SEER) registries with survival/staging (AJCC v.7) data were eligible. Modified staging was used (mAJCC v.7): group A: stages I-III (excluding T2bN0); group B: stage IVa (excluding T2bN1M0); group C: liver metastases (T2bN0/1); and group D: stage IVb (extrahepatic metastases). Survival analysis (Kaplan-Meier and Cox regression) was performed in an ENS-CCA training cohort (TC) and findings internally (ENS-CCA iVC) and externally (SEER) validated. The aim was to assess whether liver metastases (group C) had a shorter survival compared to other early stages (group A) to propose a modified version of AJCC v.8 (mAJCC v.8). A total of 574 and 4,171 patients from the ENS-CCA and SEER registries were included. Following the new classification, 19.86% and 17.31% of patients from the ENS-CCA and SEER registries were reclassified into group C, respectively. In the ENS-CCA TC, multivariable Cox regression was adjusted for obesity (p = 0.026) and performance status (P < 0.001); patients in group C (HR, 2.53; 95% CI, 1.18-5.42; P = 0.017) had a higher risk of death (vs. group A). Findings were validated in the ENS-CCA iVC (HR, 2.93; 95% CI, 2.04-4.19; P < 0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68-2.09; P < 0.001).
iCCA with liver metastases has a worse outcome than other early stages of iCCA. Given that AJCC v.8 does not take this into consideration, a modification of AJCC v.8 (mAJCC v.8), including "liver metastases: multiple liver lesions, with or without vascular invasion" as an "M1a stage," is suggested.
肝内胆管细胞癌(iCCA)伴肝转移被认为预后不良,但美国癌症联合委员会(AJCC)在缺乏淋巴结或肝外转移的情况下将其归类为早期。
来自欧洲胆管癌研究网络(ENS-CCA)和监测、流行病学和最终结果(SEER)登记处的具有生存/分期(AJCC v.7)数据的 iCCA 患者符合条件。使用改良分期(mAJCC v.7):A 组:I-III 期(不包括 T2bN0);B 组:IVA 期(不包括 T2bN1M0);C 组:肝转移(T2bN0/1);D 组:IVB 期(肝外转移)。在 ENS-CCA 培训队列(TC)中进行生存分析(Kaplan-Meier 和 Cox 回归),并在内部(ENS-CCA iVC)和外部(SEER)验证发现。目的是评估肝转移(C 组)是否比其他早期阶段(A 组)的生存率更短,以提出 AJCC v.8 的改良版本(mAJCC v.8)。ENS-CCA 和 SEER 登记处共纳入 574 例和 4171 例患者。根据新分类,ENS-CCA 和 SEER 登记处分别有 19.86%和 17.31%的患者重新分类为 C 组。在 ENS-CCA TC 中,多变量 Cox 回归调整了肥胖(p=0.026)和表现状态(P<0.001);C 组患者(HR,2.53;95%CI,1.18-5.42;P=0.017)死亡风险更高(与 A 组相比)。ENS-CCA iVC(HR,2.93;95%CI,2.04-4.19;P<0.001)和 SEER 登记处(HR,1.88;95%CI,1.68-2.09;P<0.001)的验证结果一致。
肝内胆管细胞癌伴肝转移的预后比其他早期肝内胆管细胞癌差。由于 AJCC v.8 没有考虑到这一点,建议对 AJCC v.8 进行修改(mAJCC v.8),包括“肝转移:多个肝内病变,伴或不伴血管侵犯”作为“M1a 期”。